Connection

Co-Authors

This is a "connection" page, showing publications co-authored by LINGEGOWDA SELANERE MANGALA and SUNILA PRADEEP.
Connection Strength

1.896
  1. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754.
    View in: PubMed
    Score: 0.142
  2. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.
    View in: PubMed
    Score: 0.132
  3. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
    View in: PubMed
    Score: 0.130
  4. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
    View in: PubMed
    Score: 0.121
  5. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407.
    View in: PubMed
    Score: 0.056
  6. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2022 Jun 10; 13(1):3352.
    View in: PubMed
    Score: 0.052
  7. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
    View in: PubMed
    Score: 0.050
  8. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.
    View in: PubMed
    Score: 0.047
  9. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.
    View in: PubMed
    Score: 0.046
  10. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019 12 24; 29(13):4389-4406.e10.
    View in: PubMed
    Score: 0.044
  11. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
    View in: PubMed
    Score: 0.042
  12. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.
    View in: PubMed
    Score: 0.041
  13. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.
    View in: PubMed
    Score: 0.040
  14. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.
    View in: PubMed
    Score: 0.040
  15. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.
    View in: PubMed
    Score: 0.039
  16. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018 02 02; 9(1):476.
    View in: PubMed
    Score: 0.039
  17. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
    View in: PubMed
    Score: 0.038
  18. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.
    View in: PubMed
    Score: 0.038
  19. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74.
    View in: PubMed
    Score: 0.038
  20. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71.
    View in: PubMed
    Score: 0.038
  21. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
    View in: PubMed
    Score: 0.038
  22. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310.
    View in: PubMed
    Score: 0.038
  23. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).
    View in: PubMed
    Score: 0.038
  24. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.037
  25. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 2017 Apr 18; 8(16):27380-27392.
    View in: PubMed
    Score: 0.037
  26. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519.
    View in: PubMed
    Score: 0.036
  27. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016 11 08; 24(5):685-700.
    View in: PubMed
    Score: 0.036
  28. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631.
    View in: PubMed
    Score: 0.036
  29. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. 2016 08 08; 30(2):273-289.
    View in: PubMed
    Score: 0.035
  30. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39.
    View in: PubMed
    Score: 0.034
  31. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96.
    View in: PubMed
    Score: 0.034
  32. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.034
  33. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.
    View in: PubMed
    Score: 0.034
  34. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016 08 18; 35(33):4312-20.
    View in: PubMed
    Score: 0.034
  35. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016 Jan; 63(1):159-72.
    View in: PubMed
    Score: 0.033
  36. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.
    View in: PubMed
    Score: 0.031
  37. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
    View in: PubMed
    Score: 0.031
  38. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.
    View in: PubMed
    Score: 0.030
  39. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.030
  40. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.